Q4 2025 Lantern Pharma Inc Earnings Call Transcript
Key Points
- Lantern Pharma Inc (LTRN) achieved clinical validation across multiple programs in 2025, establishing a foundation for future growth.
- The company reported a 19% reduction in total operating expenses year over year, reflecting disciplined execution.
- Lantern Pharma Inc (LTRN) received FDA IND clearance for its pediatric CNS cancer program, marking a significant regulatory milestone.
- The company's AI-driven clinical pipeline encompasses multiple drug candidates with a combined estimated annual market potential exceeding $15 billion.
- Lantern Pharma Inc (LTRN) has successfully dosed over 100 patients across its programs, demonstrating clear linkage to mechanisms and patient value.
- Lantern Pharma Inc (LTRN) reported a net loss of approximately $17.1 million for the full year 2025.
- The company anticipates needing to raise substantial additional funding in the near future to continue operations.
- There was a slight increase in general and administrative expenses for the full year 2025, primarily due to business development and investor relations expenditures.
- Lantern Pharma Inc (LTRN) faces challenges in the evolving treatment landscape, requiring protocol amendments and FDA feedback.
- The company is subject to risks and uncertainties that may cause actual results to differ materially from forward-looking statements.
Good afternoon, and welcome to our fourth quarter and year-end 2025 earnings call. As a reminder, this call is being recorded. (Operator Instructions) A webcast replay of today's conference call will be available on our website at lanternpharma.com shortly after the call.
We issued a press release after market close today, summarizing our financial results and progress across the company for the fourth quarter and year ended December 31, 2025. A copy of this release is available through our website at lanternpharma.com, where you will also find a link to the slides management will be referencing on today's call.
We would like to remind everyone that remarks about future expectations, performance, estimates and prospects constitute forward-looking statements for purposes of Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Lantern Pharma cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated. A number of factors could cause actual results to differ
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
